When you purchase through links on our site , we may earn an affiliate mission . Here ’s how it works .
Clinical trials for the COVID-19 vaccine developed by AstraZeneca and Oxford University have been put on hold after a participant developed a suspected untoward chemical reaction , Stat News first reported .
But do n’t worry ; this is exactly how clinical trials are mean to work . The conclusion to intermit the run also does n’t have in mind the vaccine caused the adverse issue ; the side effect could have occurred by chance in someone who received the vaccinum .
The pharmaceutic ship’s company AstraZeneca " voluntarily paused vaccination to allow review of rubber information by an independent committee , " a company spokespersonsaid in a statement . " This is a routine activity that has to happen when there is a potentially unexplained illness in one of the trials . " In large clinical trials with thousands of participant , " illnesses will happen by chance , " but each malady must be severally reviewed to unveil whether the chemical reaction was at all related to the vaccine , the spokesperson added .
bear on : Here are the most promising coronavirus vaccinum candidates out there
The player — a woman in the U.K. — show neurological symptom often consort with transverse myelitis , a condition where the spinal cord becomes conflagrate , AstraZeneca CEO Pascal Soriot told investors during a private call on Sep. 9,according to Stat News . These symptom can include pain , muscle weakness , palsy and vesica problems . Soriot confirmed that the patient did receive the real COVID-19 vaccinum and not a placebo barb , but her diagnosing of transverse myelitis has yet to be confirmed and may or may not be linked to the vaccine itself .
" This is the whole point of doing these phase 2 , phase 3 tribulation , " Dr. Phyllis Tien , an infectious disease physician at the University of California , San Francisco , told The Times . " I think halting the trial until the safety board can figure out whether or not this was directly related to the vaccinum is a expert idea . "
The AstraZeneca trials were put on intermission in July , as well , when a different patient developed neurologic symptom , Soriot said during the group discussion call , accord to Stat News . However , that patient was subsequently diagnosed withmultiple sclerosisand the company determined that the illness was not link to the vaccination , he said .
Related:5 dangerous myth about vaccine
AstraZeneca is one of nine drug companies to publicly pledge that they will not release acoronavirusvaccine without tolerable base hit and efficacy data from " large , high - timbre clinical trials,“The New York Times reported Sep. 8 . In recent week , President Donald Trump has teased that a COVID-19 vaccine could be useable before election day , rear concern from scientist and wellness official that a vaccinum might be released without clear trial impression that it ’s safe and in reality works .
— 11 ( sometimes ) lethal diseases that hop across species
— 14 Coronavirus myths busted by science
— The 12 mortal viruses on world
" I love the fact that the nine big vaccine manufacturers … said they would not do anything previous , " Dr. Judith Feinberg , the frailty president for research in medicine at West Virginia University , told The Times . " I think there ’s enormous imperativeness to do something premature . "
Originally publish on Live Science .
